EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB)

Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C. Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company’s shares. The change comes after Genmab and partner AbbVie announced that their Phase 3 EPCORE DLBCL-1 trial found no meaningful improvement in the overall survival for EPKINLY (epcoritamab) monotherapy when compared to standard treatments in second-line diffuse large B-cell lymphoma (DLBCL) ...